Newsroom

Sorted by: Latest

-

Janus Living Announces Launch of Public Offering of Class A-1 Common Stock

DENVER--(BUSINESS WIRE)--Janus Living, Inc. (NYSE: JAN) (“Janus Living”), a pure-play senior housing real estate investment trust (REIT), announced today the launch of its public offering of 25,000,000 shares of its Class A-1 common stock pursuant to a registration statement on Form S-11 filed with the Securities and Exchange Commission (the “SEC”). Janus Living expects to grant the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its Class A-1 common stock. Janu...
-

Arm Holdings plc Reports Results for the Second Quarter of the Fiscal Year Ending 2027

CAMBRIDGE, England--(BUSINESS WIRE)--Arm Holdings plc (NASDAQ: ARM), the company that is building the future of computing, has today published a letter to its shareholders containing the company’s results for its second quarter of fiscal year 2027, which ended Sept. 30, 2026. The letter is available on its investor relations website (https://investors.arm.com/financials/quarterly-annual-results). The shareholder letter will also be furnished to the Securities and Exchange Commission (SEC) on a F...
-

Onterris Reports Third Quarter Results, Reiterates Full-Year 2026 Guidance, Announces Completed Acquisitions, and Provides Update on Board-led Strategic Review Process

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Onterris, Inc. (the “Company,” “Onterris” or “ONT”) (NYSE: ONT), a global environmental solutions company solving complex challenges for planet and progress, today announced results for the third quarter ended September 30, 2026. Onterris President and Chief Executive Officer, Vijay Manthripragada, commented, “Our third-quarter results demonstrate meaningful progress against our objectives for the year. Compared to prior year, we delivered higher Adjusted EBI...
-

Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026. Third Quarter 2026 Financial and Business Highlights Total net sales of $27.2 million, including $23.3 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 13% year-over-year. Gross margin of 62....
-

AI and Frontline Teams Adoption Drive Strong Q2 CX Growth at 8x8

CAMPBELL, Calif.--(BUSINESS WIRE)--8x8, Inc. (NASDAQ: EGHT) released its Q2 FY27 momentum metrics, with growth in the adoption of AI solutions, communication API interactions, and more....
-

Aeva Expands Product Portfolio for Optical Connectivity Market

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aeva® (Nasdaq: AEVA), a leader in next-generation sensing and perception systems, today introduced an expanded portfolio of solutions within Optical Connectivity, Aeva’s business that leverages proprietary high-power, low noise optical sources and multiwavelength integrated silicon photonics technologies for next-generation AI data centers. Aeva is engaged with a growing number of optical solutions providers and AI compute companies, driven by our ability...
-

Permian Resources Declares Quarterly Cash Dividend

MIDLAND, Texas--(BUSINESS WIRE)--Permian Resources Corporation (“Permian Resources” or the “Company”) (NYSE: PR) today announced that its Board of Directors declared a quarterly base cash dividend of $0.16 per share of Class A common stock, or $0.64 per share on an annualized basis. The base dividend is payable on December 31, 2026 to shareholders of record as of December 17, 2026. About Permian Resources Headquartered in Midland, Texas, Permian Resources is an independent oil and natural gas c...
-

Magnolia Oil & Gas Corporation Announces Third Quarter 2026 Results

HOUSTON--(BUSINESS WIRE)--Magnolia Oil & Gas Corporation Announces Third Quarter 2026 Results...
-

Xencor Reports Third Quarter 2026 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026. “Xencor’s lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcinoma, and our plans for moving XmAb819 into earlier lines of treatment as a mono...
-

Lumen Technologies Reports Solid Third Quarter 2026 Results; Strategic Growth and Operating Leverage Gain Momentum

DENVER--(BUSINESS WIRE)--Lumen Technologies, Inc. (Nasdaq: LUMN) today reported third quarter 2026 results, delivering strong Strategic revenue growth and remaining on track for the adjusted EBITDA inflection in 2026. The company continues progress toward its financial goals and strategic transformation with expanded adoption of its Network-as-a-Service (NaaS) platform and advanced portfolio simplification. Among the company’s highlights from the quarter: Financial Performance: Third-quarter re...